Intrarenal renin-angiotensin system and counteracting protective mechanisms in angiotensin II-dependent hypertension

Acta Physiologica Hungarica

Volumn 94, Issue 1-2, 2007, Pages 31-48

  Mitchell, Kenneth D ^a   Botros, F T ^a   Navar, L G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Angiotensinogen; ANP; Bradykinin; COX metabolites; Heme heme oxygenase; Hypertension; Nitric oxide

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; CARBON MONOXIDE; HEME; HEME OXYGENASE; ICOSANOID; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW;

ANGIOTENSIN II; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARBON MONOXIDE; CYCLOOXYGENASE INHIBITORS; EICOSANOIDS; HEME; HEME OXYGENASE (DECYCLIZING); HYPERTENSION; HYPERTENSION, RENAL; RENIN-ANGIOTENSIN SYSTEM;

EID: 34248219007     PISSN: 0231424X     EISSN: 15882683     Source Type: Journal    
DOI: 10.1556/APhysiol.94.2007.1-2.5     Document Type: Article

References (142)

1. Luke RG: Essential hypertension: A renal disease? A review and update of the evidence. Hypertension 21, 380-390 (1993)
2. Navar LG: The kidney in blood pressure regulation and development of hypertension. Medical Clinics of North America 81, 1165-1198 (1997)
3. Navar LG, Hamm LL: The kidney in blood pressure regulation. In: Wilcox CS, (ed.) Atlas of Diseases of the Kidney. Hypertension and the Kidney. Philadelphia: Current Medicine, Inc., 1.1-1.22 (1999)
4. Navar LG: The intrarenal renin-angiotensin system in hypertension. Kidney Int. 65(4), 1522-1532 (2004)
5. Guyton AC, Hall JE, Coleman TG, Manning Jr. RD, Norman Jr. RA: The dominant role of the kidneys in long-term arterial pressure regulation in normal and hypertensive states. In: Laragh JH, Brenner BM (eds) Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press, Ltd., 1311-1326 (1995)
6. Cowley Jr. AW: Long-term control of arterial blood pressure. Physiol. Rev. 72, 231-300 (1992)
7. Navar LG: The role of the kidneys in hypertension. J. Clin. Hypertens. (Greenwich) 7(9), 542-549 (2005)
8. Ritz E, Fliser D, Siebels M: Pathophysiology of hypertensive renal damage. Am. J. Hypertens. 6, 241S-244S (1993)
9. Smithies O, Kim H-S, Takahashi N, Edgell MH: Importance of quantitative genetic variations in the etiology of hypertension. Kidney Int. 58, 2265-2280 (2000)
10. Lalouel J-M, Rohrwasser A, Terreros D, Morgan T, Ward K: Angiotensinogen in essential hypertension: From genetics to nephrology. J. Am. Soc. Nephrol. 12, 606-615 (2001)
11. Mitchell KD, Mullins JJ: ANG II dependence of tubuloglomerular feedback responsiveness in hypertensive ren-2 transgenic rats. Am. J. Physiol-Renal Physiol. 268, F821-F828 (1995)
12. Sigmund CD, Jones CA, Kane CM, Wu C, Lang JA, Gross KW: Regulated tissue- and cell-specific expression of the human renin gene in transgenic mice. Circ. Res. 70, 1070-1079 (1992)
13. Yang G, Sigmund CD: Developmental expression of human angiotensinogen in transgenic mice. Am. J. Physiol-Renal Physiol. 274, F932-F939 (1998)
14. Ding Y, Davisson RL, Hardy DO, Zhu L-J, Merrill DC, Catterall JF et al.: The kidney androgen-regulated protein promoter confers renal proximal tubule cell-specific and highly androgen-responsive expression on the human angiotensinogen gene in transgenic mice. J. Biol. Chem. 272, 28142-28148 (1997)
15. Sigmon DH, Beierwaltes WH: Renal nitric oxide and angiotensin II interaction in renovascular hypertension. Hypertension 22, 237-242 (1993)
16. Guan S, Fox J, Mitchell KD, Navar LG: Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats. Hypertension 20, 763-767 (1992)
17. Imamura A, Mackenzie HS, Lacy ER, Hutchison FN, Fitzgibbon WR, Ploth DW: Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats. Kidney Int. 47, 1394-1402 (1995)
18. Navar LG, Zou L, Von Thun AM, Wang C-T, Imig JD, Mitchell KD: Unraveling the mystery of Goldblatt Hypertension. News in Physiological Sciences 13, 170-176 (1998)
19. Navar LG, Von Thun AM, Zou L, El-Dahr SS, Mitchell KD: Enhancement of intrarenal angiotensin II levels in 2 kidney 1 clip and angiotensin II induced hypertension. Blood Pressure 4 (Suppl 2), 88-92 (1995)
20. Inscho EW, Carmines PK, Cook AK, Navar LG: Afferent arteriolar responsiveness to altered perfusion pressure in renal hypertension. Hypertension 15, 748-752 (1990)
21. Morishita R, Higaki J, Okunishi H, Tanaka T, Ishii K, Nagano M et al.: Changes in gene expression of the renin-angiotensin system in two-kidney, one clip hypertensive rats. J. Hypertens. 9, 187-192 (1991)
22. Von Thun AM, Vari RC, El-Dahr SS, Navar LG: Augmentation of intrarenal angiotensin II levels by chronic angiotensin II infusion. Am. J. Physiol-Renal Physiol. 266, F120-F128 (1994)
23. Von Thun AM, El-Dahr SS, Vari RC, Navar LG: Modulation of renin-angiotensin and kallikrein gene expression in experimental hypertension. Hypertension 23 (Suppl I), I-131-I-136 (1994)
24. Gorbea-Oppliger VJ, Melaragno MG, Potter GS, Petit RL, Fink GD: Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects. J. Pharmacol. Exp. Ther. 271, 804-810 (1994)
25. Hu L, Catanzaro DF, Pitarresi TM, Laragh JH, Sealey JE: Identical hemodynamic and hormonal responses to 14-day infusions of renin or angiotensin II in conscious rats. J. Hypertens. 16, 1285-1298 (1998)
26. Zou L, Imig JD, Von Thun AM, Hymel A, Ono H, Navar LG: Receptor-mediated intrarenal ANG II augmentation in ANG II-infused rats. Hypertension 28, 669-677 (1996)
27. Zou L, Hymel A, Imig JD, Navar LG: Renal accumulation of circulating angiotensin II in angiotensin II-infused rats. Hypertension 27 (part 2), 658-662 (1996)
28. Navar LG, Imig JD, Zou L, Wang C-T: Intrarenal production of angiotensin II. Sem. Nephrol. 17, 412-422 (1997)
29. Navar LG, Harrison-Bernard LM, Wang C-T, Cervenka L, Mitchell KD: Concentrations and actions of intraluminal angiotensin II. J. Am. Soc. Nephrol. 10, S189-S195 (1999)
30. Mitchell KD, Jacinto SM, Mullins JJ: Proximal tubular fluid, kidney, and plasma levels of angiotensin II in hypertensive ren-2 transgenic rats. Am. J. Physiol-Renal Physiol. 273, F246-F253 (1997)
31. Siragy HM, Howell NL, Ragsdale NV, Carey RM: Renal interstitial fluid angiotensin: Modulation by anesthesia, epinephrine, sodium depletion and renin inhibition. Hypertension 25, 1021-1024 (1995)
32. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 39, 129-134 (2002)
33. Braam B, Mitchell KD, Fox J, Navar LG: Proximal tubular secretion of angiotensin II in rats. Am. J. Physiol-Renal Physiol. 264, F891-F898 (1993)
34. Merrill DC, Thompson MW, Carney CL, Granwehr BP, Schlager G, Robillard JE et al.: Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J. Clin. Invest. 97(4), 1047-1055 (1996)
35. Kobori H, Harrison-Bernard LM, Navar LG: Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J. Am. Soc. Nephrol. 12, 431-439 (2001)
36. Smithies O, Kim HS: Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc. Natl. Acad. Sci. USA 91, 3612-3615 (1994)
37. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M et al.: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J. Clin. Invest. 99, 1786-1797 (1997)
38. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A et al.: Molecular basis of human hypertension: role of angiotensinogen. Cell 71, 169-180 (1992)
39. Schunkert H, Ingelfinger JR, Jacob H, Jackson B, Bouyounes B, Dzau VJ: Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II. Am. J. of Physiology-Endocrinology and Metabolism 263, E863-E869 (1992)
40. Kobori H, Harrison-Bernard LM, Navar LG: Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension 37, 1329-1335 (2001)
41. Favaro S, Baggio B, Castellani A, Corsini A, Antonello A, Todesco S et al.: Urinary angiotensinogen loss in chronic proteinuric glomerulonephritis. Int. Urol. Nephrol. 4, 195-198 (1972)
42. Yoshiya M, Tsutsui Y, Itoh N, Okamoto H: Angiotensinogen excretion in rat urine: effects of lipopolysaccharide treatment and sodium balance. Japan J. Pharmacol. 57, 37-44 (1991)
43. Wang E, Yayama K, Takano M, Okamoto H: Sexual dimorphism of urine angiotensinogen excretion in the rat. Japan J. Pharmacol. 64, 243-250 (1994)
44. Pedraza-Chaverri J, Cruz C, Ibarra-Rubio ME, Hernandez C, Tapia E, Pena JC: Urinary excretion of renin and angiotensinogen in nephrotic rats. Nephron 57, 106-108 (1991)
45. Kobori H, Harrison-Bernard LM, Navar LG: Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 61(2), 579-585 (2002)
46. Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG: Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension 41(1), 42-49 (2003)
47. Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H, Ozawa Y, Hering-Smith KS, Hamm LL et al.: Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension 44(2), 223-229 (2004)
48. Prieto-Carrasquero MC, Kobori H, Ozawa Y, Gutierrez A, Seth D, Navar LG: AT1 receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Am. J. Physiol.-Renal Physiol. 289, F632-F637 (2005)
49. Navar LG, Prieto-Carrasquero MC, Kobori H (2006): Molecular aspects of the renal renin-angiotensin system. In: Re R, DiPette DJ, Schiffrin EL, Sowers JR (Eds.) Molecular Mechanisms in Hypertension. Taylor & Francis Group, pp. 3-14
50. Wilcox CS, Welch WJ, Snellen H: Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int. 40, 1090-1997 (1991)
51. Pollock DM: Renal endothelin in hypertension. [Review] [91 refs]. Current Opinion in Nephrology & Hypertension 9(2), 157-164 (2000)
52. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG: Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Hypertension 95, 588-593 (1997)
53. Peters H, Border WA, Noble NA: Targeting TGF-b overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. 54, 1570-1580 (1998)
54. Dahlfors G, Chen Y, Wasteson M, Arnqvist HJ: PDGF-BB-induced DNA synthesis is delayed by angiotensin II in vascular smooth muscle cells. Am. J. Physiol. 274, H1742-H1748 (1998)
55. Chua CC, Hamdy RC, Chua BH: Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim. Biophys. Acta 1401, 187-194 (1998)
56. Wolf G (2002): The Renin-angiotensin System and Progression of Renal Diseases. Hamburg: Karger.
57. Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau P et al.: Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J. Clin. Invest. 101, 1530-1537 (1998)
58. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q, Taylor WR et al.: p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ. Res. 80, 45-51 (1997)
59. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, Stahl RAK et al.: Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: Evidence for an involvement of protein kinase C. Kidney Int. 55, 252-260 (1999)
60. Kopkan L, Castillo A, Navar LG, Majid DS: Enhanced superoxide generation modulates renal function in ANG II-induced hypertensive rats. Am. J. Physiol-Renal Physiol. 290(1), F80-F86 (2006)
61. Patterson ME, Mouton CR, Mullins JJ, Mitchell KD: Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension. Am. J. Physiol-Renal Physiol. 289(4), F754-F759 (2005)
62. Kranzhofer R, Browatzki M, Schmidt J, Kubler W: Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochemical and Biophysical Research Communications 257, 826-828 (1999)
63. Tayeh MA, Scicli AG: Angiotensin II and bradykinin regulate the expression of P-selectin on the surface of endothelial cells in culture. Proc. Assoc. Am. Physicians 110, 412-421 (1998)
64. Braun-Dullaeus RC, Mann MJ, Ziegler A, von der Leyen HE, Dzau VJ: A novel role for the cyclin-dependent kinase inhibitor p27 (Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J. Clin. Invest. 104, 815-823 (1999)
65. Fukai T, Siegfried MR, Ushio-Fukai M, Griendling KK, Harrison DG: Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ. Res. 85, 23-28 (1999)
66. Meng S, Cason GW, Gannon AW, Racusen LC, Manning RD Jr.: Oxidative stress in Dahl salt-sensitive hypertension. Hypertension 41(6), 1346-1352 (2003)
67. Meng S, Roberts LJ, Cason GW, Curry TS, Manning RD Jr.: Superoxide dismutase and oxidative stress in Dahl salt-sensitive and -resistant rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283(3), R732-R738 (2002)
68. Schnackenberg CG, Welch WJ, Wilcox CS: Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic. Role of nitric oxide. Hypertension 32, 59-64 (1998)
69. Nishiyama A, Fukui T, Fujisawa Y, Rahman M, Tian R-X, Kimura S et al.: Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension 37, 77-83 (2001)
70. Schnackenberg CG, Wilcox CS: The SOD mimetic tempol restores vasodilation in afferent arterioles of experimental diabetes. Kidney Int. 59, 1859-1864 (2001)
71. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. [Review] [93 refs]. Circ. Res. 86(5), 494-501 (2000)
72. Samuni A, Godinger D, Aronovitch J, Russo A, Mitchell JB: Nitroxides block DNA scission and protect cells from oxidative damage. Biochemistry 30(2), 555-561 (1991)
73. Mitchell JB, DeGraff W, Kaufman D, Krishna MC, Samuni A, Finkelstein E et al. Inhibition of oxygendependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch. Biochem. Biophys. 289(1), 62-70 (1991)
74. Schnackenberg CG: Oxygen radicals in cardiovascular-renal disease. Curr. Opin. Pharmacol. 2(2), 121-125 (2002)
75. Gryglewski RJ, Palmer RMJ, Moncada S: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320, 454-456 (1986)
76. Wilcox CS, Welch WJ: Interaction between nitric oxide and oxygen radicals in regulation of tubuloglomerular feedback. Acta Physiol. Scand. 168(1), 119-124 (2000)
77. Chin SY, Wang C-T, Majid DSA, Navar LG: Renoprotective effects of nitric oxide in angiotensin IIinduced hypertension in the rat. Am. J. Physiol-Renal Physiol. 274, F876-F882 (1998)
78. Chin SY, Pandey KN, Shi S-J, Kobori H, Moreno C, Navar LG: Increased activity and protein expression of calcium-dependent nitric oxide synthases in the renal cortex of angiotensin II-infused hypertensive rats. Am. J. Physiol-Renal Physiol. 277, F797-F804 (1999)
79. Hennington BS, Zhang H, Miller MT, Granger JP, Reckelhoff JF: Angiotensin II stimulates synthesis of endothelial nitric oxide synthase. Hypertension 31 (part 2), 283-288 (1998)
80. 2-receptors enhances the slow vasopressor response to angiotensin II. Hypertension 23, 646-652 (1994)
81. Lin K-F, Chao J, Chao L: Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension 26 (part 1), 847-853 (1995)
82. Johnston CI, Hodsman GP, Kohzuki M, Casley DJ, Fabris B, Phillips PA: Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. American Journal of Medicine 87, 24S-28S (1989)
83. Mattson DL, Cowley Jr. AW: Kinin actions on renal papillary blood flow and sodium excretion. Hypertension 21, 961-965 (1993)
84. 2, water, and sodium excretion. Hypertension 25, 1008-1013 (1995)
85. Omoro SA, Majid DSA, El-Dahr SS, Navar LG: Kinin influences on renal regional blood flow responses to angiotensin-converting enzyme inhibition in dogs. Am. J. Physiol-Renal Physiol. 276, F271-F277 (1999)
86. Yu H, Carretero OA, Juncos LA, Garvin JL: Biphasic effect of bradykinin on rabbit afferent arterioles. Hypertension 32, 287-292 (1998)
87. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO et al.: A gene for high urinary kallikrein may protect against hypertension in Utah kindred. Hypertension 13, 3-8 (1989)
88. Woodley-Miller C, Chao J, Chao L: Restriction fragment length polymorphism mapped in spontaneously hypertensive rats using kallikrein probes. J. Hypertens. 7, 865-871 (1989)
89. Majima M, Yoshida O, Mihara H, Muto T, Mizogami S, Kuribayashi Y et al.: High senstivity to salt in kininogen-deficient Brown Norway Katholiek rats. Hypertension 22, 705-714 (1993)
90. Majima M, Mizogami S, Kuribayashi Y, Katori M, Oh-ishi S: Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 24, 111-119 (1994)
91. 2-receptor knockout mice. Hypertension 32, 503-509 (1998)
92. Cervenka L, Malý J, Karasová L, Simová M, Vítko S, El-Dahr SS et al.: Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice. Hypertension 37, 967-973 (2001)
93. Wang J, Xiong W, Yang Z, David T, Dewey MJ, Chao J et al.: Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23, 236-243 (1994)
94. 2 receptor. Hypertension 29, 488-493 (1997)
95. Wang C, Chao L, Chao J: Direct delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J. Clin. Invest. 95, 1710-1716 (1995)
96. Nasjletti A: The role of eicosanoids in angiotensin-dependent hypertension. Hypertension 31 (part 2), 194-200 (1998)
97. Schuijt MP, de Vries R, Saxena PR, Jan Danser AH: Prostanoids, but not nitric oxide, counterregulate angiotensin II mediated vasoconstriction in vivo. Eur. J. Pharmacol. 428(3), 331-336 (2001)
98. Toda N, Miyazaki M: Angiotensin-induced relaxation in isolated dog renal and cerebral arteries. Am. J. Physiol. 240(2), H247-H254 (1981)
99. Lin L, Nasjletti A: Role of endothelium-derived prostanoid in angiotensin-induced vasoconstriction. Hypertension 18, 158-164 (1991)
100. Pagano PJ, Lin L, Sessa WC, Nasjletti A: Arachidonic acid elicits endothelium-dependent release from the rabbit aorta of a constrictor prostanoid resembling prostaglandin endoperoxides. Circ. Res. 69(2), 396-405 (1991)
101. Kawada N, Dennehy K, Solis G, Modlinger P, Hamel R, Kawada JT et al.: TP receptors regulate renal hemodynamics during angiotensin II slow pressor response. Am. J. Physiol-Renal Physiol. 287(4), F753-F759 (2004)
102. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD et al.: Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Invest. 110(1), 61-69 (2002)
103. 2 receptors in control of murine renal hemodynamics. Am. J. Physiol. Heart Circ. Physiol. 280, H327-H333 (2001)
104. 1 receptor mediates pain perception and regulates blood pressure. J. Clin. Invest. 107(3), 325-331 (2001)
105. 2 actions in the microcirculation of the rat kidney. Am. J. Physiol-Renal Physiol. 279, F755-F764 (2000)
106. Inscho EW, Carmines PK, Navar LG: Prostaglandin influences on afferent arteriolar responses to vasoconstrictor agonists. Am. J. Physiol-Renal Physiol. 259, F157-F163 (1990)
107. Narumiya S, Sugimoto Y, Seyberth HW, Nusing RM: Prostanoid receptors: structures, properties, and functions. Physiological Reviews 79, 1193-1226 (2000)
108. Opay AL, Mouton CR, Mullins J, Mitchell KD: Cyclooxygenase-2 inhibition normalized arterial blood pressure in CYP1A1-Ren2 transgenic rats with inducible Ang II-dependent malignant hypertension. Am. J. Physiol-Renal Physiol. 291(3), F612-F618 (2006)
109. Meyer M, Forssmann WG (1997): Renal actions of atrial natriuretic peptide. In: Samson WK, Levin ER (Eds) Natriuretic Peptides in Health and Disease. Totawa, NJ: Humana Press Inc. pp 147-170
110. Levin ER, Samson W, Gardner DG: Natriuretic peptides. N. Engl. J. Med. 339, 321-328 (1998)
111. Drewett JG, Garbers DL: The family of guanylyl cyclase receptors and their ligands. Endocrine Reviews 15, 135-162 (1994)
112. Pandey KN (1997): Physiology of the natriuretic peptides: Gonadal function. In: Samson WK, Levin ER (Eds) Contemporary Endocrinology: Natriuretic Peptides in Health and Disease. Totowa, NJ: Humana Press, Inc. pp. 171-191
113. Garbers DL: Guanylyl cyclase receptors and their endocrine, paracrine and autocrine ligands. Cell 71, 1-4 (1992)
114. Pandey KN (1996): Vascular action: Natriuretic peptide receptor. In: Sowers JR (Ed.) Contemporary Endocrinology: Endocrinology of the Vasculature. Totowa NJ: Humana Press, Inc., pp. 255-267
115. Shi SJ, Nguyen HT, Sharma GD, Navar LG, Pandey KN: Genetic disruption of atrial natriuretic peptide receptor-A alters renin and angiotensin II levels. Am. J. Physiol-Renal Physiol. 281(4), F665-F673 (2001)
116. Shi SJ, Vellaichamy E, Chin SY, Smithies O, Navar LG, Pandey KN: Natriuretic peptide receptor A mediates renal sodium excretory responses to blood volume expansion. Am. J. Physiol-Renal Physiol. 285(4), F694-F702 (2003)
117. Smithies O, Maeda N: Gene targeting approaches to complex genetic diseases: Atherosclerosis and essential hypertension. Proc. Natl. Acad. Sci. USA 92, 5266-5272 (1995)
118. Oliver PM, Fox JE, Kim R, Rockman HA, Kim H-S, Reddick RL et al.: Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor-A. Proc. Natl. Acad. Sci. USA 94, 14730-14735 (1994)
119. Oliver PM, John SW, Purdy KE, Kim R, Maeda N, Goy MF et al.: Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-dependent manner. Proc. Natl. Acad. Sci. USA 95, 2547-2551 (1998)
120. Pandey KN, Oliver PM, Maeda N, Smithies O: Hypertension associated with decreased testosterone levels in natriuretic peptide receptor-A gene-knockout and gene-duplicated mutant mouse models. Endocrinology 11, 5112-5119 (1999)
121. Abraham NG, Kappas A: Heme oxygenase and the cardiovascular-renal system. Free Radic. Biol. Med. 39(1), 1-25(2005)
122. Penney DG: Review: Hemodynamic response to carbon monoxide. Environmental Health Perspectives 77, 121-130 (1988)
123. Johnson RA, Kozma F, Colombari E: Carbon monoxide: from toxin to endogenous modulator of cardiovascular functions. Brazilian Journal of Medical and Biological Research 32, 1-14 (1999)
124. Botros FT, Navar LG: Interaction between endogenously-produced carbon monoxide and nitric oxide in regulation of renal afferent arterioles. Am. J. Physiol. Heart Circ. Physiol. (2006)
125. Croft KD, McGiff JC, Sanchez-Mendoza A, Carroll MA: Angiotensin II releases 20-HETE from rat renal microvessels. Am. J. Physiol-Renal Physiol. 279, F544-F551 (2000)
126. Levere RD, Martasek P, Escalante B, Schwartzman ML, Abraham NG: Effect of heme arginate administration on blood pressure in spontaneously hypertensive rats. J. Clin. Invest. 86(1), 213-219 (1990)
127. Botros FT, Laniado-Schwartzman M, Abraham NG: Regulation of cyclooxygenase- and cytochrome p450-derived eicosanoids by heme oxygenase in the rat kidney. Hypertension 39 (2 Pt 2), 639-644 (2002)
128. Sessa WC, Abraham NG, Escalante B, Schwartzman ML: Manipulation of cytochrome P-450 dependent renal thromboxane synthase activity in spontaneously hypertensive rats. J. Hypertens. 7(1), 37-42 (1989)
129. Sacerdoti D, Escalante B, Abraham NG, McGiff JC, Levere RD, Schwartzman ML: Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 243, 388-390 (1989)
130. Maines MD: The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 37, 517-554 (1997)
131. Hu Y, Ma N, Yang M, Semba R: Expression and distribution of heme oxygenase-2 mRNA and protein in rat kidney. J. Histochem. Cytochem. 46(2), 249-256 (1998)
132. Da Silva J-L, Zand BA, Yang LM, Sabaawy HE, Lianos E, Abraham NG: Heme oxygenase isoform-specific expression and distribution in the rat kidney. Kidney Int. 59, 1448-1457(2001)
133. Sikorski EM, Hock T, Hill-Kapturczak N, Agarwal A: The story so far: Molecular regulation of the heme oxygenase-1 gene in renal injury. Am. J. Physiol-Renal Physiol. 286(3), F425-F441 (2004)
134. Haugen EN, Croatt AJ, Nath KA: Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int. 58, 144-152 (2000)
135. Aizawa T, Ishizaka N, Taguchi J, Nagai R, Mori I, Tang SS et al.: Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection. Hypertension 35(3), 800-806 (2000)
136. Li P, Jiang H, Yang L, Quan S, Dinocca S, Rodriguez F et al.: Angiotensin II induces carbon monoxide production in the perfused kidney: relationship to protein kinase C activation. Am. J. Physiol-Renal Physiol. 287(5), F914-F920 (2004)
137. Botros FT, Schwartzman ML, Stier CT Jr., Goodman AI, Abraham NG: Increase in heme oxygenase-1 levels ameliorates renovascular hypertension. Kidney Int. 68(6), 2745-2755 (2005)
138. Yang L, Quan S, Nasjletti A, Laniado-Schwartzman M, Abraham NG: Heme oxygenase-1 gene expression modulates angiotensin II-induced increase in blood pressure. Hypertension 43(6), 1221-1226 (2004)
139. Rodriguez F, Zhang F, Dinocca S, Nasjletti A: Nitric oxide synthesis influences the renal vascular response to heme oxygenase inhibition. Am. J. Physiol-Renal Physiol. 284(6), F1255-F1262 (2003)
140. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN: Bilirubin is an antioxidant of possible physiological importance. Science 235(4792), 1043-1046 (1987)
141. Quan S, Yang L, Shnouda S, Schwartzman ML, Nasjletti A, Goodman AI et al.: Expression of human heme oxygenase-1 in the thick ascending limb attenuates angiotensin II-mediated increase in oxidative injury. Kidney Int. 65(5), 1628-1639 (2004)
142. Pflueger A, Croatt AJ, Peterson TE, Smith LA, d'Uscio LV, Katusic ZS et al.: The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am. J. Physiol-Renal Physiol. 288(3), F552-F558 (2005)